Infectex , a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize...
In early September the investment committee of Maxwell Biotech Venture Fund (“MBVF”), founded with the participation of the Russian Government’s RVC, approved the binding terms and the amount of an investment in a newly established private...
From 13 to 15 November 2012, the World Trade Center, Moscow, will host the XVI Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer market. The event will be attended by Skolkovo Biomedical...